These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Formulating appropriate nursing diagnoses for the patient receiving tissue-type plasminogen activator. Brooks-Brunn JA Heart Lung; 1987 Nov; 16(6 Pt 2):787-91. PubMed ID: 3119523 [No Abstract] [Full Text] [Related]
24. Paraplegia subsequent to administration of tissue plasminogen activator and intravenous heparin following myocardial infarction--a case report. DePorto R; Ahn JH; Gianutsos JG J Spinal Cord Med; 2000; 23(2):150-2. PubMed ID: 10914357 [TBL] [Abstract][Full Text] [Related]
25. Bleeding secondary to the use of thrombolytic agent in a patient with recent renal lithotripsy. Bleckley JE; Morse HG J S C Med Assoc; 1991 Nov; 87(11):549-50. PubMed ID: 1766245 [TBL] [Abstract][Full Text] [Related]
26. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Califf RM; Topol EJ; George BS; Boswick JM; Abbottsmith C; Sigmon KN; Candela R; Masek R; Kereiakes D; O'Neill WW Am J Med; 1988 Sep; 85(3):353-9. PubMed ID: 3137818 [TBL] [Abstract][Full Text] [Related]
27. Splenic hemorrhage after tissue plasminogen activator for acute myocardial infarction. Blankenship J; Indeck M N Engl J Med; 1991 Sep; 325(13):969. PubMed ID: 1908949 [No Abstract] [Full Text] [Related]
28. Is there a new i.v. push t-PA? Sweeney E Heartbeat; 1990; 1(3):3. PubMed ID: 2127727 [No Abstract] [Full Text] [Related]
29. Markers of reperfusion after thrombolytic therapy for acute myocardial infarction. Lieberman KS J Emerg Nurs; 1995 Apr; 21(2):112-5. PubMed ID: 7776600 [No Abstract] [Full Text] [Related]
30. Front-loaded accelerated infusions of tissue plasminogen activator: putting a better foot forward. Vaughan DE; Braunwald E J Am Coll Cardiol; 1992 Apr; 19(5):1076-8. PubMed ID: 1552098 [No Abstract] [Full Text] [Related]
31. Effect of serum total cholesterol on hemorrhagic complications following thrombolytic therapy for acute myocardial infarction. Caputo R; Corrao JM; Lew R; Becker RC Cardiology; 1991; 79(3):211-8. PubMed ID: 1769036 [TBL] [Abstract][Full Text] [Related]
32. Cholesterol embolization syndrome after intravenous tissue plasminogen activator for acute myocardial infarction. Arora RR; Magun AM; Grossman M; Katz J Am Heart J; 1993 Jul; 126(1):225-8. PubMed ID: 8322670 [No Abstract] [Full Text] [Related]
33. Cardiac tamponade following treatment with tissue plasminogen activator: an atypical hemodynamic response to pericardiocentesis. Barrington WW; Smith JE; Himmelstein SI Am Heart J; 1991 Apr; 121(4 Pt 1):1227-9. PubMed ID: 1901191 [No Abstract] [Full Text] [Related]
38. Thrombolytic therapy orders and record sheets: nursing care made easier. Rafter RH J Emerg Nurs; 1988; 14(4):237-9. PubMed ID: 3137388 [No Abstract] [Full Text] [Related]
39. Bilateral vitreous hemorrhages as a consequence of thrombolytic therapy successfully treated with vitrectomy in a patient without diabetes. Grekos ZG; Schocken DD Am Heart J; 1995 Sep; 130(3 Pt 1):611-2. PubMed ID: 7661080 [No Abstract] [Full Text] [Related]